Myriad Raises 2026 guidance on stronger results and planned prenatal health sale
Myriad Genetics reported higher-than-expected Q3 2026 revenue driven by a 7% sequential increase in average revenue per test. The company also raised its full-year 2026 revenue expectations and agreed to sell its Prenatal Health business to Labcorp.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed